The NPPA has introduced new policies that enhance patients' access to medicines. The first price order saw the stabilization of the price of 35 pharmaceutical formulations, including medicines used in the treatment of various forms of cancer. Specifically, the price of gemcitabine injection was set at 5,623,07 INR per vial.

Other important elements have been added to the list of prices, such as two antibiotic solutions, ciprofloxacin and dexamethasone at 2.71 INR per ml, and metformin at 13.92 INR per tablet. Another important element is the revision of the maximum dose of a drug called oxaliplatin, a chemotherapy drug used to treat gastrointestinal tumors like colorectal cancers. These price policy revisions were implemented to improve patients' access to medicines, making it easier for them to find treatments against cancer and other medical issues.

This reform is an example of how science and progress can be used to improve the quality of life of patients and reduce unnecessary costs. The NPPA continues to work to ensure that medicines are available, helping patients find the best possible treatment. The effectiveness of these price policies is evident when considering the results achieved with the stabilization of the price of 35 pharmaceutical formulations and the revision of the maximum dose of a specific drug used to treat gastrointestinal tumors.

These changes clearly show how science can be used to improve the accessibility of medicines and increase the quality of life of patients. In conclusion, the NPPA has introduced new policies that have allowed better access to medicines for patients, making them easier to find and allowing them to benefit from better treatments. This article focuses on some of the most significant changes that have occurred in the pharmaceutical sector, showing how science and progress can be used to improve the quality of life of patients and reduce unnecessary costs.